XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Anaplastic Thyroid Cancer · Thyroid Cancer · BRAF Mutation-Related Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
Contact: Study coordinator (Veronica Bedard) · 617-582-7323
Contact: Study coordinator (Theodora Pappa, MD, PhD) · theodora_pappa@dfci.harvard.edu · 617-732-5666
Contact: Principal Investigator (Theodora Pappa, MD, PhD)
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Contact: Study coordinator (Siddharth Sheth, MD) · siddharth.sheth@unchealth.unc.edu
Contact: Study coordinator (Melissa B Flores) · melissa_flores@med.unc.edu · (919)-966-4432

Study leads

Siddharth Sheth, DO MPH
Principal Investigator
UNC Lineberger Comprehensive Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Saint Petersburg, Russia

Sacituzumab govitEcan in THYroid Cancers

Differentiated Thyroid Cancer · Anaplastic Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Barcelona, Spain · Ferrol, Spain

GETNE Registration of Thyroid Cancer

Thyroid Cancer

Abroad (travel likely)Recruiting

Barcelona, Spain